Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $92.8 million.

  • Autolus Therapeutics' Operating Expenses rose 3674.2% to $92.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $325.1 million, marking a year-over-year increase of 4199.91%. This contributed to the annual value of $251.5 million for FY2024, which is 3867.0% up from last year.
  • Per Autolus Therapeutics' latest filing, its Operating Expenses stood at $92.8 million for Q3 2025, which was up 3674.2% from $82.1 million recorded in Q2 2025.
  • Autolus Therapeutics' Operating Expenses' 5-year high stood at $262.1 million during Q4 2021, with a 5-year trough of -$40.6 billion in Q3 2021.
  • In the last 5 years, Autolus Therapeutics' Operating Expenses had a median value of $44.4 million in 2023 and averaged -$2.1 billion.
  • Its Operating Expenses has fluctuated over the past 5 years, first tumbled by 17135559.02% in 2021, then surged by 25608.96% in 2023.
  • Over the past 5 years, Autolus Therapeutics' Operating Expenses (Quarter) stood at $262.1 million in 2021, then plummeted by 94.29% to $15.0 million in 2022, then surged by 256.09% to $53.3 million in 2023, then skyrocketed by 42.47% to $75.9 million in 2024, then increased by 22.3% to $92.8 million in 2025.
  • Its Operating Expenses stands at $92.8 million for Q3 2025, versus $82.1 million for Q2 2025 and $74.2 million for Q1 2025.